Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Liquidia (NASDAQ:LQDA) had its target price raised by investment analysts at HC Wainwright from $58.00 to $65.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 91.51% from the company’s current price.

Several other brokerages have also recently weighed in on LQDA. Royal Bank Of Canada set a $130.00 price objective on Liquidia in a research note on Friday, July 24th. Needham & Company LLC dropped their price objective on Liquidia from $72.00 to $58.00 and set a “buy” rating for the company in a report on Wednesday. Jefferies Financial Group raised Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. Stephens set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Finally, Wells Fargo & Company lifted their target price on Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $77.85.

Liquidia Stock Performance

LQDA opened at $33.94 on Thursday. The firm has a market cap of $3.04 billion, a P/E ratio of 24.77 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The company has a 50 day simple moving average of $62.30 and a two-hundred day simple moving average of $61.74. Liquidia has a 1-year low of $21.94 and a 1-year high of $93.61.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the prior year, the firm posted ($0.49) earnings per share. The firm’s revenue for the quarter was up 1842.1% on a year-over-year basis. Equities analysts forecast that Liquidia will post 2.05 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 9,218 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $262,528.64. Following the transaction, the insider owned 126,368 shares of the company’s stock, valued at approximately $3,598,960.64. This trade represents a 6.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,101 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $31,356.48. Following the completion of the sale, the insider owned 64,846 shares of the company’s stock, valued at approximately $1,846,814.08. This represents a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 745,194 shares of company stock valued at $41,081,702 over the last three months. 25.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently made changes to their positions in the stock. Quantinno Capital Management LP lifted its holdings in shares of Liquidia by 3.6% during the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after purchasing an additional 589 shares during the last quarter. Arizona State Retirement System raised its position in shares of Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after purchasing an additional 900 shares during the last quarter. Swiss National Bank boosted its stake in Liquidia by 1.3% in the 1st quarter. Swiss National Bank now owns 120,400 shares of the company’s stock worth $4,544,000 after purchasing an additional 1,600 shares in the last quarter. Valmark Advisers Inc. boosted its stake in Liquidia by 10.2% in the 1st quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock worth $775,000 after purchasing an additional 1,905 shares in the last quarter. Finally, Globeflex Capital L P acquired a new stake in Liquidia in the 2nd quarter worth approximately $175,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia will retain the ability to commercialize YUTREPIA for pulmonary arterial hypertension (PAH), reassuring investors that the product can remain available without interruption. The settlement resolves patent, antitrust, trade-secret and contract disputes. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, and Liquidia reported $396.1 million in cash and equivalents as of September 30. Management expects ongoing sales and existing cash to fund settlement payments and clinical development without needing additional financing.
• Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” with a $59 target. Needham maintained a “buy” rating despite reducing its target to $58.
• Neutral Sentiment: Unusually high options activity accompanied the move, with traders purchasing 30,594 call contracts—more than double typical call volume—indicating increased speculative interest but not guaranteeing further gains.
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the transactions were scheduled and insiders retained substantial holdings, they are a limited standalone signal, although broader insider activity remains heavily weighted toward sales. Liquidia insider trading report
• Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million through 2026 and 2027, substantially reducing its cash cushion and potentially limiting investments in growth and research.
• Negative Sentiment: Liquidia agreed not to appeal a patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential commercial opportunities. Investors are therefore weighing the removal of legal risk against the settlement’s large financial cost and reduced product scope. Zacks settlement analysis

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).